<DOC>
	<DOCNO>NCT00627146</DOCNO>
	<brief_summary>Compared placebo , treatment ChAgly CD3 beneficial effect preservation beta cell function metabolic outcome type 1 diabetic patient recent clinical onset disease persist 48 month administration . The investigator also hypothesize type 1 diabetic patient recent clinical onset disease compare placebo , ChAgly CD3 safe well tolerate 18 48 month administration , base assessment clinical laboratory adverse event .</brief_summary>
	<brief_title>Extension Phase II Therapeutic Trial With Humanized Non-Mitogenic CD3 ( ChAgly CD3 ) Monoclonal Antibody Recently Diagnosed Type 1 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects Type 1 diabetes mellitus include phase II therapeutic trial humanize nonmitogenic CD3 monoclonal antibody ( ChAgly CD3 ) time clinical diagnosis agree likely comply investigator 's instruction Any illness , opinion investigator , might confound result study pose additional risk patient Use illicit drug consumption alcohol ( &gt; 3 beers/day ) Being legally incapacitate , significant emotional problem time study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Diabetes Mellitus , type 1</keyword>
	<keyword>ChAgly CD3</keyword>
</DOC>